OSI-774 in advanced Esophageal Cancer: A phase II study.

被引：0
|
作者：
Radovich, D [1 ]
Kelsen, D [1 ]
Shah, M [1 ]
Klimstra, D [1 ]
Gavin, SG [1 ]
Munoz, D [1 ]
Ilson, DH [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4077
引用
收藏
页码：332S / 332S
页数：1
相关论文
共 50 条
  • [31] Phase II study of paclitaxel and cisplatin in advanced esophageal cancer: A Chinese esophageal cancer group
    Huang, J
    Cai, GR
    Zhang, JM
    Wang, WJ
    Da Chu, T
    Sun, Y
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 356S - 356S
  • [32] Phase II study of erlotinib (Tarceva, OSI774) in women with recurrent or metastatic endometrial cancer - NCICIND 148.
    Oza, AM
    Elit, L
    Eisenhauer, E
    Hoskins, PJ
    Biagi, J
    Carey, M
    Dubuc-Lissoir, J
    Dundas, G
    Stuart, G
    Matthews, S
    Tsao, M
    Dancey, J
    Fyles, A
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6094S - 6094S
  • [33] Interferon-alpha promotes the anti-proliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines
    Yang, JL
    Qu, XJ
    Russell, PJ
    Goldstein, D
    CANCER LETTERS, 2005, 225 (01) : 61 - 74
  • [34] Phase I, pharmacokinetic (PK) and biologic study of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin in patients with advanced solid malignancies
    Patnaik, A
    Goetz, A
    Hammond, LA
    Tolcher, AW
    Schwartz, G
    Hill, M
    Zitelli, A
    Wood, D
    Nadler, P
    Rowinsky, EK
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S54 - S54
  • [35] A phase II study of neoadjuvant chemotherapy with DCS for resectable advanced esophageal cancer
    Kitadani, Junya
    Nakamura, Masaki
    Ojima, Toshiyasu
    Katsuda, Masahiro
    Hayata, Keiji
    Yamaue, Hiroki
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [36] Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): Early termination due to increased toxicities
    Messersmith, WA
    Laheru, DA
    Senzer, NN
    Donehower, RC
    Grouleff, P
    Rogers, T
    Kelley, SK
    Ramies, DA
    Lum, BL
    Hidalgo, M
    CLINICAL CANCER RESEARCH, 2004, 10 (19) : 6522 - 6527
  • [37] Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models
    Higgins, B
    Kolinsky, K
    Smith, M
    Beck, G
    Rashed, M
    Adames, V
    Linn, M
    Wheeldon, E
    Gand, L
    Birnboeck, H
    Hoffmann, G
    ANTI-CANCER DRUGS, 2004, 15 (05) : 503 - 512
  • [38] Carboplatin plus etoposide regimen in advanced breast cancer. A phase II study.
    Deltetto, F
    Durando, A
    Camanni, M
    Pesola, D
    Sberveglieri, M
    Arese, P
    Massobrio, M
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 1997, 18 (03) : 185 - 187
  • [39] Docetaxel plus ifosfamide in advanced breast cancer refractory to anthracyclines: A phase II study.
    Lorusso, V
    Crucitta, E
    Sambiasi, D
    Attolico, M
    De Lena, M
    ANNALS OF ONCOLOGY, 2000, 11 : 36 - 37
  • [40] Raltirexed (Tomudex), in elderly patients with advanced colorectal cancer (CRC): A phase II study.
    Comandone, A
    Oliva, C
    Dal Canton, O
    Boglione, A
    Cutin, SC
    Brizzi, MP
    Pochettino, P
    Bergnolo, P
    ANNALS OF ONCOLOGY, 2000, 11 : 57 - 57
12345